FSSAI issues notices to Nestlé India, Zydus Wellness over product claims
Nestle India is in focus.
· LiveMint Companies
FSSAI has issued notices to Nestlé India over claims on Lactogen Pro 1 and Nan Excella Pro Stage 1, seeking scientific evidence. Zydus Wellness also received a notice over Complan, but said its claims are factual and backed by science.
The analysis
Against that, the stock is -1.5% on the day at ₹1,223.90, and has returned -15.7% over three months. It sits 20% below its 52-week high. The fmcg sector has moved -6.4% over the same period, so Nestle India is running 9.3 points behind its peers.
For Nestle India, the question is how much of this is already reflected in the price and how much re-rates the fmcg peer set alongside it.
Market context
- The company directly in focus is NESTLEIND.
- Sector exposure: FMCG.
In this story
Related coverage
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
How Bajaj Consumer Care is defying an FMCG slowdown
Hindustan Unilever Q4 Preview: Price cuts, slow demand, regional competition to hurt topline
India-UK trade pact: Pernod, Diageo Scotch imports under tax scanner, says report
Tata Consumer Q2 Results: Date, Time, Dividend News, Earnings Call Schedule And More